Inventiva
Market Cap
€86.8m
Last Updated
2019/12/10 22:59 UTC
Data Sources
Company Financials +
Executive Summary
Inventiva S.A., a biopharmaceutical company, develops drugs for the treatment of fibrotic, cancer, and orphan diseases.
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
+ 1 more risk
Snowflake Analysis
Mediocre balance sheet and overvalued.
Share Price & News
How has Inventiva's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IVA's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
11.6%
IVA
3.4%
FR Biotechs
1.2%
FR Market
1 Year Return
-48.6%
IVA
-29.7%
FR Biotechs
20.8%
FR Market
Return vs Industry: IVA underperformed the French Biotechs industry which returned -29.7% over the past year.
Return vs Market: IVA underperformed the French Market which returned 20.8% over the past year.
Shareholder returns
| IVA | Industry | Market | |
|---|---|---|---|
| 7 Day | 11.6% | 3.4% | 1.2% |
| 30 Day | 16.0% | 4.4% | -0.7% |
| 90 Day | 61.9% | -5.5% | 3.6% |
| 1 Year | -48.6%-48.6% | -29.6%-29.7% | 25.1%20.8% |
| 3 Year | n/a | -58.8%-58.8% | 41.1%27.4% |
| 5 Year | n/a | -59.4%-60.0% | 77.1%50.8% |
Price Volatility Vs. Market
How volatile is Inventiva's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 weeks ago | Simply Wall St
Imagine Owning Inventiva (EPA:IVA) While The Price Tanked 56%3 months ago | Simply Wall St
What Should You Know About Inventiva S.A.'s (EPA:IVA) Long Term Outlook?5 months ago | Simply Wall St
Those Who Purchased Inventiva (EPA:IVA) Shares A Year Ago Have A 74% Loss To Show For ItValuation
Is Inventiva undervalued compared to its fair value and its price relative to the market?
1.76x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate IVA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate IVA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: IVA is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: IVA is unprofitable, so we can't compare its PE Ratio to the French market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IVA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IVA is good value based on its PB Ratio (1.8x) compared to the FR Biotechs industry average (2x).
Next Steps
Future Growth
How is Inventiva forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
6.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IVA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IVA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IVA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IVA's revenue is expected to decline over the next 3 years (-19.4% per year).
High Growth Revenue: IVA's revenue is forecast to decline over the next 3 years (-19.4% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IVA's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Inventiva performed over the past 5 years?
-44.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IVA is currently unprofitable.
Growing Profit Margin: IVA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IVA is unprofitable, and losses have increased over the past 5 years at a rate of -44.1% per year.
Accelerating Growth: Unable to compare IVA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IVA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).
Return on Equity
High ROE: IVA has a negative Return on Equity (-91.26%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Inventiva's financial position?
Financial Position Analysis
Short Term Liabilities: IVA's short term assets (€52.4M) exceed its short term liabilities (€16.5M).
Long Term Liabilities: IVA's short term assets (€52.4M) exceed its long term liabilities (€3.0M).
Debt to Equity History and Analysis
Debt Level: IVA's debt to equity ratio (0.4%) is considered satisfactory.
Reducing Debt: IVA's debt to equity ratio has increased from 0.2% to 0.4% over the past 5 years.
Balance Sheet
Inventory Level: IVA has a low level of unsold assets or inventory.
Debt Coverage by Assets: IVA's debt is covered by short term assets (assets are 340.1x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IVA has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: IVA has less than a year of cash runway if free cash flow continues to reduce at historical rates of -36.3% each year
Next Steps
Dividend
What is Inventiva's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate IVA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate IVA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IVA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IVA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IVA's dividend in 3 years as they are not forecast to pay a notable one for the French market.
Next Steps
Management
What is the CEO of Inventiva's salary, the management and board of directors tenure and is there insider trading?
7.3yrs
Average management tenure
CEO
Frederic Cren 0
8.9yrs
Tenure
€375,840
Compensation
Mr. Frederic Cren is a Co-Founder of Inventiva S.A. since and also serves as its Chief Executive Officer since 2011. Mr. Cren has been Chairman at Inventiva S.A. since May 2016 and also serves as its Direc ...
CEO Compensation Analysis
Compensation vs Market: Frederic's total compensation ($USD417.00K) is above average for companies of similar size in the French market ($USD320.27K).
Compensation vs Earnings: Frederic's compensation has increased whilst the company is unprofitable.
Management Age and Tenure
7.3yrs
Average Tenure
Experienced Management: IVA's management team is seasoned and experienced (7.3 years average tenure).
Board Age and Tenure
1.6yrs
Average Tenure
55yo
Average Age
Experienced Board: IVA's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 25.9%.
Management Team
Marie-Paul Richard (64yo)
Chief Medical Officer
- Tenure: 1.2yrs
Kristina Meyer
Head of Business Development
- Tenure: 0yrs
Pierre Broqua
Co-Founder
- Tenure: 3.6yrs
- Compensation: €262.58k
Frederic Cren
Co-Founder
- Tenure: 8.9yrs
- Compensation: €375.84k
Jean Volatier
Chief Financial Officer
- Tenure: 7.3yrs
Nathalie Harroy
Head of Human Resources
- Tenure: 0yrs
Olivier Lacombe
Head of Pharmacokinetics
- Tenure: 0yrs
Christian Montalbetti
Head of Chemistry
- Tenure: 0yrs
Irena Konstantinova
Head of Biology & Pharmacology
- Tenure: 0yrs
Nicolas Gueugnon
Legal Director
- Tenure: 0yrs
Board Members
Chris Buyse (55yo)
Independent Director
- Tenure: 0yrs
Annick Schwebig (68yo)
Independent Director
- Tenure: 0yrs
- Compensation: €40.00k
Jean-Louis Junien
Chairman of Scientific Advisory Board
- Tenure: 0yrs
- Compensation: €30.00k
Lucy Lu (44yo)
Independent Director
- Tenure: 1.6yrs
- Compensation: €15.00k
Pierre Broqua
Co-Founder
- Tenure: 3.6yrs
- Compensation: €262.58k
Frederic Cren
Co-Founder
- Tenure: 8.9yrs
- Compensation: €375.84k
Nawal Ouzren
Independent Director
- Tenure: 0.9yrs
Heinz Maeusli
Independent Director
- Tenure: 0.9yrs
Sven Francque
Member of Scientific Advisory Board
- Tenure: 0yrs
Manal Abdelmalek
Member of Scientific Advisory Board
- Tenure: 0yrs
Company Information
Inventiva S.A.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Inventiva S.A.
- Ticker: IVA
- Exchange: ENXTPA
- Founded: 2011
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €86.760m
- Shares outstanding: 26.53m
- Website: https://www.inventivapharma.com
Number of Employees
Location
- Inventiva S.A.
- 50 rue de Dijon
- Daix
- Burgundy
- 21121
- France
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| IVA | ENXTPA (Euronext Paris) | Yes | Ordinary Shares | FR | EUR | Feb 2017 |
| 0RNK | LSE (London Stock Exchange) | Yes | Ordinary Shares | GB | EUR | Feb 2017 |
| IVEV.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Feb 2017 |
Biography
Inventiva S.A., a biopharmaceutical company, develops drugs for the treatment of fibrotic, cancer, and orphan diseases. Its lead product candidate is Lanifibranor that is in Phase IIb clinical trial to tre ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/12/10 22:59 |
| End of Day Share Price | 2019/12/10 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.